Correction to: The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis

Robert Hermann; Mats O Karlsson; Ana M Novakovic; Nadia Terranova; Markus Fluck; Alain Munafo

doi:10.1007/s40262-018-0706-x

Correction to: The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis

Clin Pharmacokinet. 2019 Mar;58(3):401. doi: 10.1007/s40262-018-0706-x.

Authors

Robert Hermann¹, Mats O Karlsson², Ana M Novakovic³, Nadia Terranova⁴, Markus Fluck³, Alain Munafo⁴

Affiliations

¹ Clinical Research Appliance (Cr Appliance), Heinrich-Vingerhut-Weg 3, 63571, Gelnhausen, Germany. [email protected].
² Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
³ Merck KGaA, Darmstadt, Germany.
⁴ Merck Institute for Pharmacometrics, Merck Serono S.A., Switzerland, an Affiliate of Merck KGaA, Darmstadt, Germany.

Abstract

The cladribine prodrug is phosphorylated intracellularly to its active product, 2-chlorodeoxyadenosine triphosphate (Cd-ATP), by deoxycytidine kinase.

Publication types

Published Erratum